Trial Profile
A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tesetaxel (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Oct 2014 Status changed from active, no longer recruiting to discontinued as reported by M.D. Anderson Cancer Center.
- 23 Apr 2014 Planned End Date changed from 1 Feb 2015 to 1 Feb 2016, as per ClinicalTrials.gov record (NCT01064713).
- 23 Apr 2013 Planned end date changed from 1 Feb 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov (NCT01064713).